The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases
British Journal of Pharmacology · 2024-06 · 181 (12) · 1695-1719
DOI: 10.1111/bph.16355 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 25.03.2024. Verfasst von Jiuguo Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Inflammasomes, DNA-Binding Proteins, Metabolic Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Traditional Chinese Medicine Bureau of Guangdong Province Research Project, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Cardio‐cerebrovascular diseases encompass pathological changes in the heart, brain and vascular system, which pose a great threat to health and well‐being worldwide. Moreover, metabolic diseases contribute to and exacerbate the impact of vascular diseases. Inflammation is a complex process that protects against noxious stimuli but is also dysregulated in numerous so‐called inflammatory diseases, one of which is atherosclerosis. Inflammation involves multiple organ systems and a complex cascade of molecular and cellular events. Numerous studies have shown that inflammation plays a vital role in cardio‐cerebrovascular diseases and metabolic diseases. The absent in melanoma 2 (AIM2) inflammasome detects and is subsequently activated by double‐stranded DNA in damaged cells and pathogens. With the assistance of the mature effector molecule caspase‐1, the AIM2 inflammasome performs crucial biological functions that underpin its involvement in cardio‐cerebrovascular diseases and related metabolic diseases: The production of interleukin‐1 beta ( IL-1β ), interleukin‐18 ( IL-18 ) and N‐terminal pore‐forming Gasdermin D fragment (GSDMD‐N) mediates a series of inflammatory responses and programmed cell death (pyroptosis and PANoptosis). Currently, several agents have been reported to inhibit the activity of the AIM2 inflammasome and have the potential to be evaluated for use in clinical settings. In this review, we systemically elucidate the assembly, biological functions, regulation and mechanisms of the AIM2 inflammasome in cardio‐cerebrovascular diseases and related metabolic diseases and outline the inhibitory agents of the AIM2 inflammasome as potential therapeutic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
- Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, China.
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China.
- Huadu District People's Hospital of Guangzhou, Guangzhou, China.
- Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Pharmacy Australia Centre of Excellence, School of Pharmacy, University of Queensland, Woolloongabba, Queensland, Australia.
ORCID-Profile: Dongmei Zhang, Zhiping Liu
Förderung
- Traditional Chinese Medicine Bureau of Guangdong Province Research Project
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Lin, J., Wang, J., Fang, J., Li, M., Xu, S., Little, P. J., Zhang, D., & Liu, Z. (2024). The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases. British Journal of Pharmacology, 181(12), 1695-1719. https://doi.org/10.1111/bph.16355
Vancouver
Lin J, Wang J, Fang J, Li M, Xu S, Little PJ, et al. The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases. British Journal of Pharmacology. 2024;181(12):1695-1719. doi:10.1111/bph.16355
BibTeX
@article{Lin2024,
author = {Lin, Jiuguo and Wang, Jiaojiao and Fang, Jian and Li, Meihang and Xu, Suowen and Little, Peter J and Zhang, Dongmei and Liu, Zhiping},
title = {The cytoplasmic sensor, the AIM2 inflammasome: A precise therapeutic target in vascular and metabolic diseases},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {12},
pages = {1695--1719},
doi = {10.1111/bph.16355}
}
EUVIMED